Relovair Bet Fuels Glaxo's $213M Theravance Stake Buy
British pharmaceutical titan GlaxoSmithKline PLC on Monday announced it will pay $213 million to increase its stake in drug development firm Theravance Inc., a milestone in a decade-long partnership focused on...To view the full article, register now.
Already a subscriber? Click here to view full article